Cardiovascular effects of the selective α1A-adrenoceptor antagonist silodosin (KMD-3213), a drug for the treatment of voiding dysfunction

Arzneimittel-Forschung/Drug Research

Volumn 56, Issue 10, 2006, Pages 682-687

  Tatemichi, Satoshi ^a   Kiguchi, Sumiyoshi ^a   Kobayashi, Mamoru ^a   Yamazaki, Yoshinobu ^a   Shibata, Nobuo ^a   Uruno, Tsutorau ^b  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

CAS 160970 54 7; KMD 3213; Silodosin, cardiovascular effects; 1 Adrenoceptor antagonist

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; POTASSIUM CHANNEL HERG; SILODOSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG INHIBITION; DYSURIA; ELECTROCARDIOGRAPHY; HEART ELECTROPHYSIOLOGY; HEART RATE; HUMAN; HUMAN CELL; MALE; NONHUMAN; PR INTERVAL; QRS COMPLEX; QT INTERVAL;

EID: 33751019990     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296773     Document Type: Article

References (26)

1. AUA Practice Guidelines Committee, AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J. Urol. 170, 530 (2003)
2. 2-and β-adrenoceptors in the urinary bladder, urethra and prostate. Br. J. Pharmacol. 147, S88 (2006)
3. 1- adrenoceptors: consensus update. Pharmacol. Rev. 47, 267 (1995)
4. Price, D. T., Schwinn, D. A., Lomasney, J. W. et al., Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J. Urol. 150, 546 (1993)
5. 1-adrenoceptor subtype mRNAs in human proximal urethra. Br. J. Pharmacol. 123, 1289 (1998)
6. 1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. J. Urol. 157, 1032 (1997)
7. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br. J. Pharmacol. 113, 723 (1994)
8. 1b-adrenergic receptor. Proc. Natl. Acad. Sci. U.S.A. 94, 11589 (1997).
9. 1-adrenoceptors and native tissues. Mol. Pharmacol. 48, 250 (1995)
10. 1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Eur. J. Pharmacol. 315, 73 (1996)
11. 1- Adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi 126, 209 (2006)
12. 1-adrenoreceptor antagonist, in human prostate and vasculature. J. Urol. 164, 578 (2000)
13. Roden, D. M., Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350, 1013 (2004)
14. Sanguinetti, M. C., Jiang, C., Curran, M. E. et al., A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81, 299 (1995)
15. Kiehn, J., Thomas, D., Karle, C, A. et al., Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch. Pharmacol. 359, 212 (1999)
16. Napolitano, C., Priori, S. G., Schwartz, P. J., Torsade de pointes. Mechanisms and management. Drugs 47, 51 (1994)
17. 1- adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch. Pharmacol. 369, 462 (2004)
18. 1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs. Int. J. Urol. 8, 177 (2001)
19. Bazett, H. C., An analysis of time-relations of the electrocardiogram. Heart 7, 353 (1920)
20. 1-adrenergic receptors by vessel bed and age. Circulation 100, 2336 (1999)
21. Guimaraes, S., Moura, D., Vascular adrenoceptors: an update. Pharmacol. Rev. 53, 319 (2001)
22. 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia: Phase III long-term study. Jpn. J. Urol. Surg. 19, 153 (2006)
23. 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. Br. J. Urol. Int. (in press)
24. Matsubara, Y., Kanazawa, T., Kojima, Y. et al., Pharmacokinetics and disposition of silodosin (KMD-3213). Yakugaku Zasshi 126, 237 (2006)
25. Redfern, W. S., Carlsson, L., Davis, A. S. et al., Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32 (2003)
26. 1-blockade in congenital long QT syndrome: investigation by exercise stress test. Jpn. Circ. J. 65, 654 (2001)